Differential Induction of Donor-reactive Foxp3 Regulatory T Cell Via Blockade of CD154 Vs CD40

Overview

Journal Am J Transplant

Publisher Elsevier

Specialty General Surgery

Date 2024 Mar 29

PMID 38552961

Authors

Danya Liu

Hongmin Yao

Ivana R Ferrer

Mandy L Ford

Affiliations

Soon will be listed here.

Abstract

Recently published studies in both murine models and a meta-analysis of non-human primate renal transplant studies showed that anti-CD154 reagents conferred a significant survival advantage over CD40 blockers in both animal models and across multiple organs. Here we sought to compare the induction of donor-reactive forkhead box P3+-induced regulatory T cells (Foxp3 iTreg) in mice treated with anti-CD154 versus anti-CD40 monoclonal antibodies (mAbs). Results indicated that while treatment with anti-CD154 mAb resulted in a significant increase in the frequency of donor-reactive CD4 Foxp3 iTreg following transplantation, treatment with anti-CD40 or Cd40 deficiency failed to recapitulate this result. Because we recently identified CD11b as an alternate receptor for CD154 during alloimmunity, we interrogated the role of CD154:CD11b interactions in the generation of Foxp3 iTreg and found that blockade of CD11b in Cd40 recipients resulted in increased donor-reactive Foxp3 iTreg as compared with CD40 deficiency alone. Mechanistically, CD154:CD11b inhibition decreased interleukin (IL)-1β from CD11b and CD11c dendritic cells, and blockade of IL-1β synergized with CD40 deficiency to promote Foxp3 iTreg induction and prolong allograft survival. Taken together, these data provide a mechanistic basis for the observed inferiority of anti-CD40 blockers as compared with anti-CD154 mAb and illuminate an IL-1β-dependent mechanism by which CD154:CD11b interactions prevent the generation of donor-reactive Foxp3 iTreg during transplantation.

References

Mailer R, Joly A, Liu S, Elias S, Tegner J, Andersson J . IL-1β promotes Th17 differentiation by inducing alternative splicing of FOXP3. Sci Rep. 2015; 5:14674. PMC: 4593960. DOI: 10.1038/srep14674. View

Wolf D, Anto-Michel N, Blankenbach H, Wiedemann A, Buscher K, Hohmann J . A ligand-specific blockade of the integrin Mac-1 selectively targets pathologic inflammation while maintaining protective host-defense. Nat Commun. 2018; 9(1):525. PMC: 5802769. DOI: 10.1038/s41467-018-02896-8. View

Wooff Y, Man S, Aggio-Bruce R, Natoli R, Fernando N . IL-1 Family Members Mediate Cell Death, Inflammation and Angiogenesis in Retinal Degenerative Diseases. Front Immunol. 2019; 10:1618. PMC: 6646526. DOI: 10.3389/fimmu.2019.01618. View

Natoli R, Fernando N, Madigan M, Chu-Tan J, Valter K, Provis J . Microglia-derived IL-1β promotes chemokine expression by Müller cells and RPE in focal retinal degeneration. Mol Neurodegener. 2017; 12(1):31. PMC: 5404662. DOI: 10.1186/s13024-017-0175-y. View

Adams A, Shirasugi N, Jones T, Durham M, Strobert E, Cowan S . Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol. 2004; 174(1):542-50. DOI: 10.4049/jimmunol.174.1.542. View

Cordoba F, Wieczorek G, Audet M, Roth L, Schneider M, Kunkler A . A novel, blocking, Fc-silent anti-CD40 monoclonal antibody prolongs nonhuman primate renal allograft survival in the absence of B cell depletion. Am J Transplant. 2015; 15(11):2825-36. DOI: 10.1111/ajt.13377. View

Chen Y, Heeger P, Valujskikh A . In vivo helper functions of alloreactive memory CD4+ T cells remain intact despite donor-specific transfusion and anti-CD40 ligand therapy. J Immunol. 2004; 172(9):5456-66. DOI: 10.4049/jimmunol.172.9.5456. View

Wekerle T, Kurtz J, Ito H, Ronquillo J, Dong V, Zhao G . Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med. 2000; 6(4):464-9. DOI: 10.1038/74731. View

Li L, Kim J, Boussiotis V . IL-1β-mediated signals preferentially drive conversion of regulatory T cells but not conventional T cells into IL-17-producing cells. J Immunol. 2010; 185(7):4148-53. PMC: 2956066. DOI: 10.4049/jimmunol.1001536. View

10.

Song L, Ma A, Dun H, Hu Y, Zeng L, Bai J . Effects of ASKP1240 combined with tacrolimus or mycophenolate mofetil on renal allograft survival in Cynomolgus monkeys. Transplantation. 2014; 98(3):267-76. PMC: 4175122. DOI: 10.1097/TP.0000000000000236. View

11.

Raffin C, Pignon P, Celse C, Debien E, Valmori D, Ayyoub M . Human memory Helios- FOXP3+ regulatory T cells (Tregs) encompass induced Tregs that express Aiolos and respond to IL-1β by downregulating their suppressor functions. J Immunol. 2013; 191(9):4619-27. DOI: 10.4049/jimmunol.1301378. View

12.

Perrin S, Magill M . The Inhibition of CD40/CD154 Costimulatory Signaling in the Prevention of Renal Transplant Rejection in Nonhuman Primates: A Systematic Review and Meta Analysis. Front Immunol. 2022; 13:861471. PMC: 9022482. DOI: 10.3389/fimmu.2022.861471. View

13.

Taylor P, Friedman T, Korngold R, Noelle R, Blazar B . Tolerance induction of alloreactive T cells via ex vivo blockade of the CD40:CD40L costimulatory pathway results in the generation of a potent immune regulatory cell. Blood. 2002; 99(12):4601-9. DOI: 10.1182/blood.v99.12.4601. View

14.

Aarts S, Seijkens T, van Dorst K, Dijkstra C, Kooij G, Lutgens E . The CD40-CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis. Front Immunol. 2018; 8:1791. PMC: 5732943. DOI: 10.3389/fimmu.2017.01791. View

15.

Liu D, Ford M . CD11b is a novel alternate receptor for CD154 during alloimmunity. Am J Transplant. 2020; 20(8):2216-2225. PMC: 7395865. DOI: 10.1111/ajt.15835. View

16.

Badell I, Russell M, Cardona K, Shaffer V, Turner A, Avila J . CTLA4Ig prevents alloantibody formation following nonhuman primate islet transplantation using the CD40-specific antibody 3A8. Am J Transplant. 2012; 12(7):1918-23. PMC: 3387300. DOI: 10.1111/j.1600-6143.2012.04029.x. View

17.

Ochando J, Homma C, Yang Y, Hidalgo A, Garin A, Tacke F . Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat Immunol. 2006; 7(6):652-62. DOI: 10.1038/ni1333. View

18.

Pinelli D, Wagener M, Liu D, Yamniuk A, Tamura J, Grant S . An anti-CD154 domain antibody prolongs graft survival and induces Foxp3(+) iTreg in the absence and presence of CTLA-4 Ig. Am J Transplant. 2013; 13(11):3021-30. PMC: 4287239. DOI: 10.1111/ajt.12417. View

19.

Larsen C, Elwood E, Alexander D, Ritchie S, Hendrix R, Tucker-Burden C . Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996; 381(6581):434-8. DOI: 10.1038/381434a0. View

20.

Lowe M, Badell I, Thompson P, Martin B, Leopardi F, Strobert E . A novel monoclonal antibody to CD40 prolongs islet allograft survival. Am J Transplant. 2012; 12(8):2079-87. PMC: 3410651. DOI: 10.1111/j.1600-6143.2012.04054.x. View